This Article Full Text Full Text (PDF) All Versions of this Article: 23/11/1979    most recent 01.ATV.0000091250.53231.4Dv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sobel, B. E. Articles by Schneider, D. J. Search for Related Content PubMed PubMed Citation Articles by Sobel, B. E. Articles by Schneider, D. J. Related Collections Secretion Catheter-based coronary and valvular interventions: other Exercise/exercise testing/rehabilitation Coagulation and fibronolysis

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23:1979.)
© 2003 American Heart Association, Inc.

Brief Reviews

Intramural Plasminogen Activator Inhibitor Type-1 and Coronary Atherosclerosis

Burton E. Sobel; Douglas J. Taatjes; David J. Schneider

From the College of Medicine, University of Vermont, Burlington.

Correspondence to Burton E. Sobel, MD, Department of Medicine, University of Vermont, Colchester Research Facility, 208 S Park Dr, Colchester, VT 05446. E-mail Burt.sobel{at}vtmednet.org

Altered expression of plasminogen activator inhibitor type-1 in vessel walls, reviewed here, might affect coronary atherogenesis. Upregulation might exacerbate vasculopathy by potentiating thrombosis and by inhibiting vascular smooth muscle cell migration, resulting in attenuation of thickness of elaborated fibrous caps implicated in the vulnerability of atheroma to rupture.

Key Words: vulnerable plaques • diabetes • fibrinolysis • atherothrombosis • coronary artery disease

This article has been cited by other articles:

				G. R. Hajer, T. W. van Haeften, and F. L.J. Visseren Adipose tissue dysfunction in obesity, diabetes, and vascular diseases Eur. Heart J., September 5, 2008; (2008) ehn387v1. [Abstract] [Full Text] [PDF]

				L. Brazionis, K. Rowley, A. Jenkins, C. Itsiopoulos, and K. O'Dea Plasminogen Activator Inhibitor-1 Activity in Type 2 Diabetes: A Different Relationship With Coronary Heart Disease and Diabetic Retinopathy Arterioscler. Thromb. Vasc. Biol., April 1, 2008; 28(4): 786 - 791. [Abstract] [Full Text] [PDF]

				P.E. Morange, N. Saut, M.C. Alessi, J.S. Yudkin, M. Margaglione, G. Di Minno, A. Hamsten, S.E. Humphries, D.A. Tregouet, and I. Juhan-Vague Association of Plasminogen Activator Inhibitor (PAI)-1 (SERPINE1) SNPs With Myocardial Infarction, Plasma PAI-1, and Metabolic Parameters: The HIFMECH Study Arterioscler. Thromb. Vasc. Biol., October 1, 2007; 27(10): 2250 - 2257. [Abstract] [Full Text] [PDF]

				S. Demyanets, C. Kaun, K. Rychli, G. Rega, S. Pfaffenberger, T. Afonyushkin, V. N. Bochkov, G. Maurer, K. Huber, and J. Wojta The inflammatory cytokine oncostatin M induces PAI-1 in human vascular smooth muscle cells in vitro via PI 3-kinase and ERK1/2-dependent pathways Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1962 - H1968. [Abstract] [Full Text] [PDF]

				Y. Mukai, C.-Y. Wang, Y. Rikitake, and J. K. Liao Phosphatidylinositol 3-kinase/protein kinase Akt negatively regulates plasminogen activator inhibitor type 1 expression in vascular endothelial cells Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1937 - H1942. [Abstract] [Full Text] [PDF]

				M.-C. Alessi and I. Juhan-Vague PAI-1 and the Metabolic Syndrome: Links, Causes, and Consequences Arterioscler. Thromb. Vasc. Biol., October 1, 2006; 26(10): 2200 - 2207. [Abstract] [Full Text] [PDF]

				Y. Chen, R. C. Budd, R. J. Kelm Jr, B. E. Sobel, and D. J. Schneider Augmentation of Proliferation of Vascular Smooth Muscle Cells by Plasminogen Activator Inhibitor Type 1 Arterioscler. Thromb. Vasc. Biol., August 1, 2006; 26(8): 1777 - 1783. [Abstract] [Full Text] [PDF]

				C. Infante-Rivard and C. R. Weinberg Parent-of-Origin Transmission of Thrombophilic Alleles to Intrauterine Growth-Restricted Newborns and Transmission-Ratio Distortion in Unaffected Newborns Am. J. Epidemiol., November 1, 2005; 162(9): 891 - 897. [Abstract] [Full Text] [PDF]

				J. K. Hennan, H. Elokdah, M. Leal, A. Ji, G. S. Friedrichs, G. A. Morgan, R. E. Swillo, T. M. Antrilli, A. Hreha, and D. L. Crandall Evaluation of PAI-039 [{1-Benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic Acid], a Novel Plasminogen Activator Inhibitor-1 Inhibitor, in a Canine Model of Coronary Artery Thrombosis J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 710 - 716. [Abstract] [Full Text] [PDF]

				M. H. Clough, D. J. Schneider, B. E. Sobel, M. F. White, M. P. Wadsworth, and D. J. Taatjes Attenuation of Accumulation of Neointimal Lipid by Pioglitazone in Mice Genetically Deficient in Insulin Receptor Substrate-2 and Apolipoprotein E J. Histochem. Cytochem., May 1, 2005; 53(5): 603 - 610. [Abstract] [Full Text] [PDF]

				D. J. Schneider, M. Hayes, M. Wadsworth, H. Taatjes, M. Rincon, D. J. Taatjes, and B. E. Sobel Attenuation of Neointimal Vascular Smooth Muscle Cellularity in Atheroma by Plasminogen Activator Inhibitor Type 1 (PAI-1) J. Histochem. Cytochem., August 1, 2004; 52(8): 1091 - 1099. [Abstract] [Full Text] [PDF]

				C Roncal, J Orbe, J.A Rodriguez, M Belzunce, O Beloqui, J Diez, and J.A Paramo Influence of the 4G/5G PAI-1 genotype on angiotensin II-stimulated human endothelial cells and in patients with hypertension Cardiovasc Res, July 1, 2004; 63(1): 176 - 185. [Abstract] [Full Text] [PDF]